ストックスクリーナーアプリを入手
27.53
4.84%
-1.40
前日終値:
$28.93
開ける：
$28.89
24時間の取引高:
997.95K
Relative Volume:
0.65
時価総額：
$2.16B
収益：
$866.00K
当期純損益:
$-283.65M
株価収益率:
-6.4518
EPS:
-4.267
ネットキャッシュフロー:
$-226.25M
1週間 パフォーマンス:
-7.90%
1か月 パフォーマンス:
-28.88%
6か月 パフォーマンス:
-18.69%
1年 パフォーマンス:
+3.69%
1日の値動き範囲:
$27.46
$28.89
1週間の範囲:
$27.46
$30.02
52週間の値動き範囲:
$22.10
$45.14
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Compare CLDX vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
27.53 | 2.16B | 866.00K | -283.65M | -226.25M | -4.267 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-22 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-04-20 | アップグレード | Barclays | Underweight → Overweight |
| 2026-03-23 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-10-13 | 開始されました | Barclays | Underweight |
| 2025-04-28 | 開始されました | Canaccord Genuity | Buy |
| 2025-03-20 | 開始されました | Morgan Stanley | Overweight |
| 2025-02-13 | 開始されました | UBS | Buy |
| 2024-10-07 | 開始されました | Citigroup | Buy |
| 2024-09-30 | 開始されました | Goldman | Neutral |
| 2024-09-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 開始されました | Stifel | Buy |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2023-12-20 | 開始されました | TD Cowen | Outperform |
| 2023-11-10 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 開始されました | Wells Fargo | Underweight |
| 2021-09-17 | 開始されました | Jefferies | Buy |
| 2021-09-10 | 開始されました | SVB Leerink | Outperform |
| 2021-07-22 | 開始されました | Guggenheim | Buy |
| 2020-02-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-07 | 開始されました | Aegis Capital | Buy |
| 2016-03-08 | ダウングレード | Jefferies | Buy → Hold |
| 2016-03-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2016-03-07 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2016-03-01 | 開始されました | H.C. Wainwright | Buy |
| 2015-08-11 | 繰り返されました | Brean Capital | Buy |
| 2015-08-11 | 繰り返されました | Oppenheimer | Outperform |
| 2015-08-11 | 繰り返されました | ROTH Capital | Buy |
| 2015-06-02 | 繰り返されました | WBB Securities | Strong Buy |
| 2014-11-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2013-07-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-03-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2013-01-10 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2012-10-02 | 繰り返されました | Oppenheimer | Outperform |
| 2012-09-14 | 繰り返されました | Cantor Fitzgerald | Buy |
すべてを表示
Celldex Therapeutics Inc (CLDX) 最新ニュース
November 9 earnings date set for Celldex Therapeutics stock - ad-hoc-news.de
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) - Lelezard
Law firm investigates Celldex Therapeutics for possible breach of fiduciary duties. - Pluang
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) - PR Newswire
FMR LLC and Abigail P. Johnson Reveal 10.7% Stake in Celldex Therapeutics Inc. - Kalkine Media
An investment firm reports a passive stake of 8.4 million shares in Celldex Therapeutics (CLDX). - Stock Titan
Celldex Therapeutics Inc (TCE2.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Celldex Therapeutics: Trying To Put Its Troubled History Behind It (NASDAQ:CLDX) - Seeking Alpha
Celldex reports Phase 3 success as HC Wainwright rates Celldex Therapeutics stock Buy - AD HOC NEWS
Celldex Therapeutics stock reports strong Phase 3 trial results - AD HOC NEWS
Celldex Therapeutics (NasdaqCM:CLDX) Stock Forecast & Analyst Predictions - Simply Wall Street
Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
What Do Positive Barzolvolimab Results Mean for Celldex (NASDAQ:CLDX)? - Kalkine Media
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64 - Moomoo
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success? - Yahoo Finance
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Yahoo Finance
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CLDX) 2026-09-22 - Seeking Alpha
Celldex Therapeutics upgraded to Buy after posi... - Pluang
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CLDX) 2026-09-22 - Seeking Alpha
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results - Benzinga
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease - Benzinga
Celldex Therapeutics Shares Fall After Phase 3 Readout Despite Positive Trial Results - Quiver Quantitative
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses - finance.yahoo.com
Celldex sinks as safety concerns cloud immune drug results - BioPharma Dive
Celldex sinks as safety concerns cloud immune drug results - finance.yahoo.com
Celldex shares slip 15% as safety concerns cloud skin drug trial win - The Economic Times
Celldex's barzolvolimab hits primary and secondary endpoints in twin Phase III CSU trials - thepharmaletter.com
4 Biotech Stocks With Key Clinical Readouts Expected This Fall - tradingview.com
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials - finance.yahoo.com
Celldex stock falls after hives trial data (CLDX:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials - marketscreener.com
Celldex announces Phase 3 barzolvolimab trials meet primary and all key secondary endpoints - tradingview.com
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 - GlobeNewswire
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 - GlobeNewswire
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials - Yahoo Finance
Celldex Therapeutics stock gains as analysts target USD 56.42 - AD HOC NEWS
Celldex Reports Positive Phase 3 Results for Barzolvolimab - Intellectia AI
Celldex Therapeutics (Nasdaq:CLDX)Stock Analysis - simplywall.st
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) - Eastern Progress
Celldex Therapeutics stock gains as analysts lift expectations - AD HOC NEWS
Celldex at Cantor conference: barzolvolimab data loom By Investing.com - Investing.com Canada
Celldex at Cantor conference: barzolvolimab data loom By Investing.com - Investing.com UK
Celldex to Present at Upcoming Investor Conference - The Manila Times
Celldex's investor talk will stream online Sept. 10 - Stock Titan
Celldex to Present at Upcoming Investor Conference - GlobeNewswire
Celldex to Present at Upcoming Investor Conference - Yahoo Finance
Celldex Therapeutics, Inc. Revenue Breakdown – NASDAQ:CLDX - TradingView
Celldex (CLDX) Quarterly Results: Profit Per Share Clears Its Benchmark on the Day; Market Reaction - vinanet.vn
Celldex Therapeutics Inc (CLDX) 財務データ
収益
当期純利益
現金流量
EPS
Celldex Therapeutics Inc (CLDX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| PEPIN RONALD | SR. VP & CBO |
Dec 15 '25 |
Option Exercise |
5.47 |
19,333 |
105,714 |
20,097 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Dec 04 '25 |
Sale |
29.09 |
4,166 |
121,210 |
30,796 |
| FREDDY A JIMENEZ | Officer |
Dec 04 '25 |
Proposed Sale |
29.10 |
4,166 |
121,210 |
0 |
| Wright Richard M. | Former Officer |
Nov 13 '25 |
Option Exercise |
14.06 |
49,298 |
692,913 |
70,131 |
| Wright Richard M. | Former Officer |
Nov 13 '25 |
Sale |
24.00 |
49,298 |
1,183,177 |
20,833 |
| RICHARD M WRIGHT | Officer |
Nov 13 '25 |
Proposed Sale |
24.00 |
49,298 |
1,183,177 |
0 |
2.71%
0.34%
大文字化:
|
ボリューム (24 時間):